Physician
Infectious Disease
Dr. Barney S. Graham, MD
Barney S. Graham practices Infectious Disease. He has 1 awards "Elected Member". Barney Graham is also a published physician. He has 101 paper published. The most recent paper is: Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.
Publications
- Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.
- Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
- Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.
- Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, ...
- Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site.
- Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.
- Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.
- History of passive antibody administration for prevention and treatment of infectious diseases.
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report.
- Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.
- Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, rando...
- Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia.
- DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild Type Glycoproteins are Safe and Immunogenic in a Phase I Clinical Trial.
- Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.
- Protecting the family to protect the child: vaccination strategy guided by RSV transmission dynamics.
- The Immune Space: A Concept and Template for Rationalizing Vaccine Development.
- HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission.
- Quantitative and Qualitative Deficits in Neonatal Lung-Migratory Dendritic Cells Impact the Generation of the CD8+ T Cell Response.
- Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy chain lineages.
- Proof of principle for epitope-focused vaccine design.
- Clonotype-specific avidity influences the dynamics and hierarchy of virus-specific regulatory and effector CD4(+) T-cell responses.
- Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation.
- Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
- Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.
- Advances in antiviral vaccine development.
- Subtypes of type I IFN differentially enhance cytokine expression by sub-optimally stimulated CD4(+) T cells.
- Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine.
- DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent ...
- HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.
- Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody.
- Therapeutic Vaccination Expands and Improves the Function of the HIV-specific Memory T Cell Repertoire.
- Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.
- Whither Monkeypox vaccination.
- Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines Delivering Simian Immunodeficiency Virus DNA.
- Neonatal CD8 T-cell Hierarchy Is Distinct from Adults and Is Influenced by Intrinsic T cell Properties in Respiratory Syncytial Virus Infected Mice.
- Future opportunities for passive immunity against viral diseases.
- Respiratory Syncytial Virus G Glycoprotein Interacts with DC-SIGN and L-SIGN to Activate ERK1 and ERK2.
- Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
- Structure of the Respiratory Syncytial Virus Fusion Glycoprotein in the Post-fusion Conformation Reveals Preservation of Neutralizing Epitopes.
- Design and Characterization of Epitope Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus.
- T Cell receptor clonotype influences epitope hierarchy in the CD8+ T cell response to respiratory syncytial virus infection.
- Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.
- GM-CSF Production Allows the Identification of Immunoprevalent Antigens Recognized by Human CD4+ T Cells Following Smallpox Vaccination.
- Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F.
- Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope.
- Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection.
- Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.
- Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination.
- A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
- Structural basis of respiratory syncytial virus neutralization by motavizumab.
- Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
- Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.
- DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases.
- Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials.
- High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
- Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model.
- Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United States.
- Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities.
- Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein.
- A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions.
- Reply to rottinghaus and poland.
- Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization.
- Viral and host factors in human respiratory syncytial virus pathogenesis.
- A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.
- Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.
- Relative dominance of epitope-specific CD8+ T cell responses in an F1 hybrid mouse model of respiratory syncytial virus infection.
- Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.
- The histopathology of fatal untreated human respiratory syncytial virus infection.
- Smallpox vaccines: Past, present, and future.
- A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.
- Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.
- Subunit recombinant vaccine protects against monkeypox.
- Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
- New approaches to vaccine adjuvants: inhibiting the inhibitor.
- Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependent.
- Respiratory syncytial virus infection in the absence of STAT 1 results in airway dysfunction, airway mucus, and augmented IL-17 levels.
- Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus.
- RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology.
- Lessons from failure--preparing for future HIV-1 vaccine efficacy trials.
- Pathogenesis of respiratory syncytial virus infection in the murine model.
- Cyclooxygenase inhibition augments allergic inflammation through CD4-dependent, STAT6-independent mechanisms.
- Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
- Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness.
- Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
- Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection.
- Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5.
- Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated...
- Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
- Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.
- RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachme...
- Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection.
- Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial vir...
- Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.
- Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis.
- IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
- Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation.
- The complex relationship between respiratory syncytial virus and allergy in lung disease.
- Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent p...
- Respiratory syncytial virus immunobiology and pathogenesis.
- NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus.
Schools
University of Kansas School of Medicine
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- Elected Member
Helpful Reviews
Similar Doctors
|
Dr. Anita Kohli, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen A. Migueles, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry W. Laughlin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David L. Blazes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Holland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yingda L. Xie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shruthi Bellapu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harry W. Haverkos, MD
This Doctor is OpenDoctor Recommended.
|